Cell and Gene Therapy CDMO Market Set to Surge with Strong Growth: Projected to Reach USD 297.03 Billion by 2034

February 14, 2025 – The Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is witnessing rapid growth, with an expected compound annual growth rate (CAGR) of 23.53% from 2025 to 2034. According to Market Research Future (MRFR), the market size is forecast to rise from USD 44.34 billion in 2025 to an impressive USD 297.03 billion by 2034.

Market Overview The Cell and Gene Therapy CDMO market is at the forefront of the expanding healthcare industry, driven by the increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes. Technological advancements, particularly in gene editing and stem cell engineering, are unlocking new opportunities in the field of personalized medicine. As these therapies grow more complex, specialized CDMOs are essential in meeting the demand for manufacturing and development services.

Scope and Segmentation The market is segmented by product into cell therapy and gene therapy. The cell therapy segment currently holds a larger share, with anticipated growth at a CAGR of 25.3% over the next decade. The gene therapy segment is also expected to see substantial growth due to an increasing number of clinical trials and therapy approvals.

Service offerings in the market include contract development, manufacturing, and analytical testing services. The application of these therapies spans oncology, immunology, neurology, cardiovascular diseases, and other conditions, with oncology leading the market share due to rising cancer rates.

Regional Analysis Geographically, North America dominated the market in 2023 and is projected to continue its lead due to strong regulatory support and the presence of major CDMOs. The Asia-Pacific region is expected to see the highest growth rate, driven by rising healthcare expenditures and growing awareness of cell and gene therapies.

Key Players Prominent players in the market include Catalent, Lonza, Thermo Fisher Scientific, and Fujifilm Diosynth Biotechnologies. These companies are leveraging investments in R&D and strategic expansions to strengthen their positions in the global market. Notable developments include the acquisition of Brammer Bio by Thermo Fisher Scientific and the scaling of Catalent's manufacturing capabilities.

Market Drivers Several factors are fueling market growth:

• Advancements in Cell and Gene Therapy: Technological breakthroughs in gene editing and stem cell research are enabling more targeted and effective therapies.
• Rising Prevalence of Chronic Diseases: The increasing global burden of chronic conditions such as cancer is pushing demand for innovative treatments.
• Technological Innovations: AI, automation, and digital technologies are enhancing manufacturing efficiency and accelerating production processes.
• Government Support: Numerous governments are backing cell and gene therapy research, recognizing its potential to transform healthcare and reduce long-term treatment costs.

Conclusion With continued innovation and growing demand, the Cell and Gene Therapy CDMO market is poised for significant expansion. As companies increasingly turn to specialized CDMOs to handle complex manufacturing processes, the industry is set to play a crucial role in the future of healthcare.